Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 19/20 | 0.81 |
| ▸ | DHFR | P00374 | 1/20 | 0.69 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.69 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5793184 | 0.99 | DHODH (0.79) | DHODHDHFRALKBH5PDE10A | |
| SCHEMBL17594376 | 0.92 | DHODH (0.73) | DHODHDHFRALKBH5 | |
| SCHEMBL23590030 | 0.92 | DHODH (0.90) | DHODHDHFRALKBH5PDE10A | |
| SCHEMBL29617666 | 0.92 | DHODH (0.90) | DHODHDHFRALKBH5PDE10A | |
| SCHEMBL13692410 | 0.90 | DHODH (0.85) | DHODHDHFRALKBH5PDE10A | |
| SCHEMBL8732559 | 0.90 | DHODH (1.00) | DHODHDHFRALKBH5 | |
| SCHEMBL13524371 | 0.88 | DHODH (0.83) | DHODHDHFRALKBH5PDE10A | |
| SCHEMBL5908719 | 0.87 | DHODH (0.95) | DHODHDHFRALKBH5PDE10A | |
| SCHEMBL13692442 | 0.86 | DHODH (0.80) | DHODHDHFRALKBH5PDE10A | |
| SCHEMBL2373278 | 0.85 | DHODH (0.74) | DHODHDHFRALKBH5PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0537191-B1 | TREATMENT OF ORGAN TRANSPLANTATION REJECTION | DU PONT MERCK PHARMA (US) | 1998-04-29 | — | — | EP | claimed |
| EP-0537191-A4 | TREATMENT OF ORGAN TRANSPLANTATION REJECTION | — | 1993-08-11 | — | — | EP | claimed |
| EP-0537191-A1 | TREATMENT OF ORGAN TRANSPLANTATION REJECTION | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-04-21 | — | — | EP | claimed |
| US-5204329-A | 4-Quinoline carboxylic acid derivatives | DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-04-20 | — | — | US | claimed |
| EP-0339485-B1 | 4-QUINOLINE CARBOXYLIC ACID DERIVATIVES USEFUL AS IMMUNOSUPPRESSIVE AGENTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-03-31 | — | — | EP | claimed |
| EP-0339484-B1 | 4-QUINOLINE CARBOXYLIC ACID DERIVATIVES USEFUL FOR TREATING SKIN AND MUCO-EPITHELIAL DISEASES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-01-20 | — | — | EP | claimed |
| WO-1991019498-A1 | TREATMENT OF ORGAN TRANSPLANTATION REJECTION | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1991-12-26 | — | — | WO | claimed |
| US-5032597-A | Antitumor | DU PONT MERCK PHARMACEUTICAL (US) | 1991-07-16 | — | — | US | claimed |
| EP-0133244-B1 | PHENYLQUINOLINECARBOXYLIC ACIDS AND DERIVATIVES AS ANTITUMOR AGENTS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-12-05 | — | — | EP | claimed |
| US-4968701-A | AUTOIMMUNE DISEASES, ORGAN TRANSPLANT REJECTION, MULTIPLE SCLEROSIS, RHEUMATOID ARTHRITIS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-11-06 | — | — | US | claimed |
| EP-0362578-A1 | Treatment of cancer in mammals by concurrent administration of 4-quinoline carboxylic acid derivatives and interleukin-2 | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-04-11 | — | — | EP | claimed |
| EP-0339484-A1 | 4-Quinoline carboxylic acid derivatives useful for treating skin and muco-epithelial diseases | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1989-11-02 | — | — | EP | claimed |
| EP-0339485-A1 | 4-Quinoline carboxylic acid derivatives useful as immunosuppressive agents | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1989-11-02 | — | — | EP | claimed |
| US-4861783-A | TOPICAL APPLICATION | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-08-29 | — | — | US | claimed |
| US-4680299-A | ANTITUMOR AGENTS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1987-07-14 | — | — | US | claimed |
| EP-0133244-A2 | Phenylquinolinecarboxylic acids and derivatives as antitumor agents | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1985-02-20 | — | — | EP | claimed |
| EP-0537191-B1 | TREATMENT OF ORGAN TRANSPLANTATION REJECTION | DU PONT MERCK PHARMA (US) | 1998-04-29 | — | — | EP | disclosed |
| WO-1997042953-A1 | USE OF BREQUINAR AND DERIVATIVES IN CHRONIC REJECTION OF ALLOGRAFTS AND XENOTRANSPLANTATION | NOVARTIS AG (CH) | 1997-11-20 | — | — | WO | disclosed |
| US-4680299-A | ANTITUMOR AGENTS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1987-07-14 | — | — | US | disclosed |
| EP-0133244-A2 | Phenylquinolinecarboxylic acids and derivatives as antitumor agents | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1985-02-20 | — | — | EP | disclosed |